Navigation Links
UC San Diego announces collaboration with Johnson & Johnson Pharmaceutical Research & Development
Date:11/20/2008

mon capabilities. We are very excited about the potential of this partnership."

The two organizations plan to create education, training and research collaborations in biomedical science, medicine and public health, with a focus on projects that lead to new clinical applications. In addition to signing the MOU, the organizations also signed the first agreement between UC San Diego Health Sciences and J&JPRD under the MOU framework a contract for UC San Diego Professor of Pharmacology Larry Brunton, Ph.D., to conduct laboratory studies to evaluate the effects of new compounds on heart tissue.


'/>"/>

Contact: Leslie Franz
lfranz@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
2. Centennial Taking Control of Your Diabetes Conference Returns to San Diego to Bring Answers, Advocacy and Hope
3. Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association
4. Car Donations: "Tired Wheels" Turned Into Donation Dollars for Ronald McDonald House Charities, San Diego
5. UC San Diego to lead nationwide program in pharmacogenomics
6. Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego
7. Graves & Thyroid Disease National Patient Conference Set for San Diego, CA
8. Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008
9. Direct From Beijing, 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Womens Cancer Awareness Special, Frosted Pink With A Twist
10. San Diego Supercomputer Center director urges academia to make cyberinfrastructure real
11. CRH Medical Corporation opens Center in San Diego California

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...SHINGTON, Dec. 4 In res...ent Agency,s (DEA) classification of boldione, des...dienedione as "anabolic steroids", under the Contr...rector and CEO of the Natural Products Association...representing retailers and manufacturers of dietar...
(Date:12/4/2009)...5 million Americans are recruited annually to part...ce for Human Research Protection (AHRP), and most ... Research institutions view payments to voluntee...ompensation for potential risks related to partici...that volunteers have a very different view of clin...
(Date:12/4/2009)... to pressure from federal regulators to crack down...AY, Dec. 4 (HealthDay News) -- The makers of 24 di...ed federal regulators with plans to curb the abuse...ompanies have been under pressure from U.S. Food a...stop the hundreds of fatal overdoses that occur wi...
(Date:12/4/2009)...olesterol-lowering drugs known as statins are amon...new study by researchers at Fred Hutchinson Cancer...t stem cell transplant patients from one of the mo... therapy: graft-versus-host disease, or GVHD. The ...of the journal Blood . , In a retrospective stud...
(Date:12/4/2009)...ADISON, Wis., Dec. 4 Whe...e Wisconsin Department of Health Services needed t... than ever before. Join Sonic Foundry, Inc. (Nas...h media webcasting and knowledge management, for a...in Department of Health Services, will share how i...
Breaking Medicine News(10 mins):Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
....Y., April 6 What is the relationship between lat...tudy examined this relationship. The scientists me... identical twins, that is, individuals with an ide...he results showed that the twin that carried the l...
...ICAGO, April 6 The U.S. economy transmits over 18...imately half of all healthcare financial transac...ing, postage and labor for manual processes in hea... administrative savings represent a bright spot --...
...Improves Survival Would Earn a 50 Percent Patient ...n Europe , According to a New Report from Decis...sion Resources, one of the world,s leading researc...attribute that most influences their prescribing d...
...INS, N.J., April 6, 2009 New head-to-head clinica...Toothbrush and Floss deliver superior plaque remov...on Healthcare Products Division of McNEIL-PPC, Inc...:, , REACH ULTRACLEAN Floss removes up to two t...
...l 6 At least 20 million Europeans suffer from chr...additional ten million experience occasional sleep...itnessed a rise in patient volume by ten per cent ... in the number of sleep service providers across E...
....Y., April 6 Computer Intuition is a psycholingui...on,s written or spoken language and retrieves info...s, Computer Intuition was used to analyze focus gr...hildren,s museum became interested in increasing i...
Other Medicine News:Health News:Effective Weight Management with Gene-Eden, a New Dietary Supplement Based on Dr. Hanan Polansky's Discovery 2Health News:Whitepaper Shines Light on Administrative Waste: Offers Practical Steps for Cutting Healthcare Costs through Existing Infrastructure, Collaboration 2Health News:Whitepaper Shines Light on Administrative Waste: Offers Practical Steps for Cutting Healthcare Costs through Existing Infrastructure, Collaboration 3Health News:Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer 2Health News:Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer 3Health News:New head-to-head clinical studies reveal Reach Ultraclean toothbrush and floss deliver superior plaque removal compared to leading competitive products 2Health News:Rise in Sleeping Disorders Triggers High Demand for Sleep Service Facilities in Europe, Notes Frost & Sullivan 2Health News:Rise in Sleeping Disorders Triggers High Demand for Sleep Service Facilities in Europe, Notes Frost & Sullivan 3Health News:Rise in Sleeping Disorders Triggers High Demand for Sleep Service Facilities in Europe, Notes Frost & Sullivan 4Health News:How Can We Improve Our Elementary School System? - Unique Market Research Analysis of the Subconscious of Parents 2
(Date:12/4/2009)... 4 Onyx Pharmaceuticals,...l host an investor teleconference and webcast. Pr...tations surrounding carfilzomib in relapsed and/or...1st American Society of Hematology (ASH) Annual Me... a.m. CT/10:00 a.m. ET on Monday, December 7, 2009...
(Date:12/4/2009)...RNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Am...l countermeasures against biological and chemical ...ata from the Company,s anthrax vaccine program sho...ntigen (rPA) based anthrax vaccine is structurally...eratures up to and including 55 degrees C. The da...
(Date:12/4/2009)...ewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex...countermeasures against biological and chemical th...ing results of a study demonstrating the effective...del in the New Zealand White (NZW) rabbit. The da...he HHS Public Health Emergency Medical Countermeas...
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Satellite Healthcare Helps Support the Cure for Kidney Disease in Sacramento 57472 1Satellite Healthcare Helps Support the Cure for Kidney Disease in Sacramento 57472 2Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 57468 1Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 57468 2Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 57468 3Sunlight Saunas Celebrates 10 Years of Industry Firsts and Announces 10th Anniversary Sweepstakes Winner 57465 1Sunlight Saunas Celebrates 10 Years of Industry Firsts and Announces 10th Anniversary Sweepstakes Winner 57465 2
...9, 2007 - ACADIA Pharmaceuticals,Inc. (Nasdaq:ACAD...ts Phase II schizophrenia co-therapy trial with AC...nverse agonist. The trial,evaluated ACP-103 co-the... commonly prescribed atypical antipsychotic drug, ...ug. The co-therapy,arms with ACP-103 demonstrated ...
...nical Data on XIENCE V Everolimus,Eluting Corona...Results from the ABSORB Bioabsorbable Stent Clinic...ewswire-FirstCall/ --,Abbott will present data f...rtfolio and pipeline during a number of late-break... Cardiology,s 56th,Annual Scientific Session bei...
Other Medicine Technology:Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 2Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 3Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 4Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 5Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 6Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 2Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 4Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 5
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products: